Magnesium Trisilicate

Identification

Name
Magnesium Trisilicate
Accession Number
DB09281
Type
Small Molecule
Groups
Approved
Description

Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Magnesium trisilicate hydrateC2E1CI501T39365-87-2FSBVERYRVPGNGG-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Alka Phenyl TabMagnesium Trisilicate (150 mg) + Aluminum hydroxide (100 mg) + Phenylbutazone (100 mg)TabletOralDuchesnay Inc.1978-12-311997-08-11Canada
Alka Phenylbutazone TabMagnesium Trisilicate (150 mg) + Aluminum hydroxide (100 mg) + Phenylbutazone (100 mg)TabletOralPro Doc Limitee1974-12-311997-08-14Canada
Gasulsol TabMagnesium Trisilicate (130 mg) + Aluminum hydroxide (195 mg)TabletOralHerbes Universelles Inc.1966-12-312009-07-15Canada
GasvaMagnesium Trisilicate (487.5 mg) + Aluminum hydroxide (260 mg)TabletOralLes Produits Gerbex Inc.1970-12-311997-08-11Canada
Gaviscon Regular StrengthMagnesium Trisilicate (14.2 mg/1) + Aluminum hydroxide (80 mg/1)Tablet, chewableOralGlaxo Smith Kline Consumer Heathcare Lp2011-06-13Not applicableUs
Mag-A-folic TabMagnesium Trisilicate (100 mg) + Folic Acid (.4 mg) + Vitamin A (2000 unit)TabletOralMetagenics, Inc.1989-12-311996-10-02Canada
Phenylone Plus TabMagnesium Trisilicate (150 mg) + Aluminum hydroxide (100 mg) + Phenylbutazone (100 mg)TabletOralMedic Laboratory LtÉe1978-12-311996-09-09Canada
R90 Anti-acide TabMagnesium Trisilicate (500 mg) + Calcium Carbonate (300 mg)TabletOralDr Reckeweg Canada1993-12-311997-08-13Canada
Spasmo Nil TabMagnesium Trisilicate (75 mg) + Aluminum hydroxide (75 mg) + Dicyclomine Hydrochloride (2.5 mg) + Dimethicone (7.5 mg)TabletOralDuchesnay Inc.1978-12-312003-07-18Canada
Categories
UNII
FML8G1U0Y3
CAS number
14987-04-3
Weight
Average: 260.857
Monoisotopic: 259.86017997
Chemical Formula
Mg2O8Si3
InChI Key
GXGAKHNRMVGRPK-UHFFFAOYSA-N
InChI
InChI=1S/2Mg.O8Si3/c;;1-9(2)7-11(5,6)8-10(3)4/q2*+2;-4
IUPAC Name
dimagnesium(2+) ion {[dioxido({[oxido(oxo)silyl]oxy})silyl]oxy}silanoylolate
SMILES
[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O

Pharmacology

Indication

For the treatment of peptic ulcers. Relieving indigestion and heartburn.

Structured Indications
Pharmacodynamics

Magnesium trisilicate works by increasing the pH of gastric juice via a neutralisation reaction. It also precipitates colloidal silica, which can coat gastrointestinal mucosa conferring further protection.

Mechanism of action

The gelatinous silicon dioxide, formed by the reaction of magnesium trisilicate with gastric contents is said to protect ulcerated mucosal surfaces and favor healing.

Absorption

The hydrated silicon dioxide formed in the stomach and passes into the intestinal track where, silica can be partly absorbed.

Volume of distribution

The hydrated silicon dioxide formed in the stomach and passes into the intestinal track.

Protein binding

33%

Metabolism
Not Available
Route of elimination

Excreted in the urine.

Half life

16-20 hours

Clearance

Maximum magnesium clearance is directly proportional to creatinine clearance.

Toxicity

Adequate doses of magnesium trisilicate may cause diarrhea due to the action of soluble magnesium salts in the enteric tract. Approx 5% of the magnesium is absorbed.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Magnesium Trisilicate.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium Trisilicate.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineMagnesium Trisilicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxyamphetamineMagnesium Trisilicate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMagnesium Trisilicate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Magnesium Trisilicate.Experimental, Illicit
AcepromazineMagnesium Trisilicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineMagnesium Trisilicate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Magnesium Trisilicate.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Magnesium Trisilicate.Experimental
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium Trisilicate.Approved
AlimemazineMagnesium Trisilicate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolMagnesium Trisilicate can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Magnesium Trisilicate.Approved
AmphetamineMagnesium Trisilicate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit
AndrostenedioneThe bioavailability of Androstenedione can be decreased when combined with Magnesium Trisilicate.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Magnesium Trisilicate.Investigational
anecortave acetateThe bioavailability of anecortave acetate can be decreased when combined with Magnesium Trisilicate.Investigational
AtamestaneThe bioavailability of Atamestane can be decreased when combined with Magnesium Trisilicate.Investigational
AtazanavirMagnesium Trisilicate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
BenzphetamineMagnesium Trisilicate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium Trisilicate.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Magnesium Trisilicate.Approved
BL-1020Magnesium Trisilicate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium Trisilicate.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Magnesium Trisilicate.Approved
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Magnesium Trisilicate.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Magnesium Trisilicate.Approved
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium Trisilicate.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Magnesium Trisilicate.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Magnesium Trisilicate.Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium Trisilicate.Approved, Vet Approved
ChlorphentermineMagnesium Trisilicate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineMagnesium Trisilicate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineMagnesium Trisilicate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlortetracyclineMagnesium Trisilicate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
CinoxacinMagnesium Trisilicate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Magnesium Trisilicate.Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium Trisilicate.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Magnesium Trisilicate.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Magnesium Trisilicate.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
Cortexolone 17α-propionateThe bioavailability of Cortexolone 17α-propionate can be decreased when combined with Magnesium Trisilicate.Investigational
CorticosteroneThe bioavailability of Corticosterone can be decreased when combined with Magnesium Trisilicate.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium Trisilicate.Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium Trisilicate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium Trisilicate.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium Trisilicate.Approved
DasatinibMagnesium Trisilicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium Trisilicate.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Magnesium Trisilicate.Approved
DemeclocyclineMagnesium Trisilicate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Magnesium Trisilicate.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Magnesium Trisilicate.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Magnesium Trisilicate.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Magnesium Trisilicate.Vet Approved
DexmethylphenidateMagnesium Trisilicate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineMagnesium Trisilicate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionMagnesium Trisilicate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Magnesium Trisilicate.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Magnesium Trisilicate.Approved
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Magnesium Trisilicate.Approved
Dipotassium phosphateMagnesium Trisilicate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineMagnesium Trisilicate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Magnesium Trisilicate.Approved
EnoxacinMagnesium Trisilicate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EquileninThe bioavailability of Equilenin can be decreased when combined with Magnesium Trisilicate.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Magnesium Trisilicate.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Magnesium Trisilicate.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Magnesium Trisilicate.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium Trisilicate.Approved
Ferric CarboxymaltoseMagnesium Trisilicate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateMagnesium Trisilicate can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateMagnesium Trisilicate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Magnesium Trisilicate.Approved
FleroxacinMagnesium Trisilicate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
fluasteroneThe bioavailability of fluasterone can be decreased when combined with Magnesium Trisilicate.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium Trisilicate.Approved
FlumequineMagnesium Trisilicate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Magnesium Trisilicate.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Magnesium Trisilicate.Approved
FluphenazineMagnesium Trisilicate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Magnesium Trisilicate.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Magnesium Trisilicate.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium Trisilicate.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Magnesium Trisilicate.Approved, Investigational, Withdrawn
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium Trisilicate.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
GarenoxacinMagnesium Trisilicate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinMagnesium Trisilicate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
GemifloxacinMagnesium Trisilicate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineMagnesium Trisilicate may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GrepafloxacinMagnesium Trisilicate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Magnesium Trisilicate.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
HydroxyamphetamineMagnesium Trisilicate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium Trisilicate.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
Iofetamine I-123Magnesium Trisilicate may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronMagnesium Trisilicate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranMagnesium Trisilicate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateMagnesium Trisilicate can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidMagnesium Trisilicate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Magnesium Trisilicate.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Magnesium Trisilicate.Approved
LevofloxacinMagnesium Trisilicate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LisdexamfetamineMagnesium Trisilicate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Magnesium Trisilicate.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium Trisilicate.Approved
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Magnesium Trisilicate.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Magnesium Trisilicate.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Magnesium Trisilicate.Approved, Investigational
MephedroneMagnesium Trisilicate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineMagnesium Trisilicate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium Trisilicate.Approved
MesoridazineMagnesium Trisilicate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethamphetamineMagnesium Trisilicate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Magnesium Trisilicate.Approved, Vet Approved
MethotrimeprazineMagnesium Trisilicate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethoxyphenamineMagnesium Trisilicate may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
Methylene blueMagnesium Trisilicate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
MethylphenidateMagnesium Trisilicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium Trisilicate.Experimental
MidomafetamineMagnesium Trisilicate may decrease the excretion rate of 3,4-Methylenedioxymethamphetamine which could result in a higher serum level.Experimental, Illicit
MinocyclineMagnesium Trisilicate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Misoprostol.Approved
MMDAMagnesium Trisilicate may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MoricizineMagnesium Trisilicate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Mycophenolic acidMagnesium Trisilicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidMagnesium Trisilicate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Magnesium Trisilicate.Investigational
NemonoxacinMagnesium Trisilicate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
NitrofurantoinThe serum concentration of Nitrofurantoin can be decreased when it is combined with Magnesium Trisilicate.Approved, Vet Approved
NorfloxacinMagnesium Trisilicate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl-estrone can be decreased when combined with Magnesium Trisilicate.Investigational
Oxolinic acidMagnesium Trisilicate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium Trisilicate.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Magnesium Trisilicate.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium Trisilicate.Approved
PazufloxacinMagnesium Trisilicate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinMagnesium Trisilicate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Magnesium Trisilicate.Approved
PerazineMagnesium Trisilicate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PerphenazineMagnesium Trisilicate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineMagnesium Trisilicate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
Pipemidic acidMagnesium Trisilicate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidMagnesium Trisilicate can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Magnesium Trisilicate.Approved, Nutraceutical
Prasterone sulfateThe bioavailability of Prasterone sulfate can be decreased when combined with Magnesium Trisilicate.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Magnesium Trisilicate.Approved
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Magnesium Trisilicate.Experimental
ProchlorperazineMagnesium Trisilicate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineMagnesium Trisilicate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineMagnesium Trisilicate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropiopromazineMagnesium Trisilicate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinMagnesium Trisilicate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineMagnesium Trisilicate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineMagnesium Trisilicate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Magnesium Trisilicate.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Magnesium Trisilicate.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Magnesium Trisilicate.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Magnesium Trisilicate.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
RitobegronMagnesium Trisilicate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinMagnesium Trisilicate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
RufloxacinMagnesium Trisilicate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
SitafloxacinMagnesium Trisilicate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Sodium glycerophosphateMagnesium Trisilicate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateMagnesium Trisilicate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Magnesium Trisilicate.Approved
SparfloxacinMagnesium Trisilicate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium Trisilicate.Approved
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Magnesium Trisilicate.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Magnesium Trisilicate.Approved
TemafloxacinMagnesium Trisilicate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThiazinamMagnesium Trisilicate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineMagnesium Trisilicate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioridazineMagnesium Trisilicate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Magnesium Trisilicate.Approved, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Magnesium Trisilicate.Approved
TolevamerThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Tolevamer.Approved
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
TriethylenetetramineMagnesium Trisilicate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrifluoperazineMagnesium Trisilicate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TriflupromazineMagnesium Trisilicate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinMagnesium Trisilicate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium Trisilicate.Experimental
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium Trisilicate.Approved
Food Interactions
Not Available

References

General References
  1. Toxnet [Link]
  2. Toxnet [Link]
  3. Sciencedirect [Link]
External Links
KEGG Drug
D03271
PubChem Compound
5311266
PubChem Substance
310265174
ChemSpider
4470779
ChEMBL
CHEMBL2096633
Wikipedia
Magnesium_trisilicate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, chewableOral
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-2.7ChemAxon
pKa (Strongest Acidic)2.65ChemAxon
pKa (Strongest Basic)-7.7ChemAxon
Physiological Charge-4ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area144.84 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity11.36 m3·mol-1ChemAxon
Polarizability11.91 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal silicates. These are inorganic compounds in which the largest oxoanion is silicate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal oxoanionic compounds
Sub Class
Alkaline earth metal silicates
Direct Parent
Alkaline earth metal silicates
Alternative Parents
Miscellaneous silicates / Metalloid salts / Inorganic salts / Inorganic oxides
Substituents
Silicate / Alkaline earth metal silicate / Inorganic oxide / Inorganic salt / Inorganic metalloid salt
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 29, 2015 09:58 / Updated on October 02, 2017 06:15